BMO Capital Starts Teva Pharma (TEVA) at Outperform

Canaccord Genuity Raises Price Target on Teva Pharma (TEVA) Following Announced Acquisition of Allergan Generics

July 28, 2015 9:23 AM EDT

Canaccord Genuity maintained a Hold rating on Teva Pharma (NYSE: TEVA), and raised the price target to $79.00 (from $63.00), following the announced acquisition of Allergan Generics for $40.5B - $33.75B in cash and $6.75B in stock. Analyst Corey Davis said that this is not a good signal about the overall future of the... More

Leerink Partners Raises Price Target to $84 on Teva Pharma (TEVA) Following Call with CFO

July 28, 2015 8:12 AM EDT

Leerink Partners reiterated an Outperform rating on Teva Pharma (NYSE: TEVA), and raised the price target to $84.00 (from $74.00), following a call with CFO Eyal Desheh. The TEVA-AGN deal is estimated to close in 1Q'16 and management still anticipates holding its annual guidance... More

Teva Pharma (TEVA) PT Bumped to $75 at Piper Jaffray

July 28, 2015 7:39 AM EDT

Piper Jaffray analyst David Amsellem lifted his price target on Teva Pharma (NYSE: TEVA) to $75.00 (from $57.00) on plans to acquire Allergan's generic business but maintained a Neutral rating.

Amsellem commented, "With Teva deadset on doubling down on its global exposure to... More

Teva Pharma (TEVA) Prelim. Q2 Revenue, EPS Outpace Views

July 27, 2015 6:14 AM EDT

Teva Pharma (NYSE: TEVA) announced preliminary financial results for the second quarter of 2015:

Revenues of approximately $4.97 billion, down 2% compared to the second quarter of 2014. Excluding the impact of foreign exchange fluctuations and the sale of U.S. OTC plants in July 2014, revenues increased 6% compared to the second quarter of 2014.Non-GAAP diluted earnings per share (EPS) of $1.43 in the second quarter of 2015, up 15% compared to the second quarter of 2014.Non-GAAP operating income of $1.6 billion, an increase of 16%... More

Teva Pharma (TEVA) to Acquire Allergan Genetics (AGN) in $40.5B Cash and Stock Deal

July 27, 2015 6:03 AM EDT

Teva Pharma (NYSE: TEVA) announced that it has signed a definitive agreement with Allergan plc (NYSE: AGN) to acquire Allergan Generics in a transaction valued at $40.5 billion. Upon closing, Allergan will receive $33.75 billion in cash and shares of Teva valued today at $6.75 billion, representing an estimated under 10% ownership stake in Teva, with the number of Teva shares determined based on Tevas volume weighted average trading prices during the 15 days prior to the announcement and five days following the announcement. Teva believes the acquisition will be significantly accretive to... More

Teva Pharma (TEVA) Nears Deal to Acquire Allergan's (AGN) Generic-Drug Business

July 26, 2015 5:23 PM EDT

Israel-based drug maker Teva Pharma (NYSE: TEVA) is in talks to acquire Allergan's (NYSE: AGN) generic-drug business, the Wall Street Journal reported on Saturday. The deal is said to be valued at about $45 billion and could be announced as soon as Monday.

If a deal is... More